Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer
Autor: | Haruaki Kato, Kazuyoshi Iijima, Teppei Yamamoto, Tomomi Haba, Hiroshi Oike, Tomohiko Oguchi, Masashi Shiozaki, Osamu Ishizuka |
---|---|
Rok vydání: | 2020 |
Předmět: |
PSA-PFS
PSA progression-free survival medicine.medical_specialty Neutropenia Urology 030232 urology & nephrology Castration resistant lcsh:RC870-923 OS overall survival 03 medical and health sciences Prostate cancer 0302 clinical medicine White blood cell Internal medicine medicine mCRPC metastatic castrate-resistant prostate cancer GS Gleason Score Adverse effect Castration-resistant prostate cancer FN febrile neutropenia NLR neutrophil/lymphocyte ratio PSA prostate-specific antigen Cabazitaxel Leukopenia business.industry CRPC castrate-resistant prostate cancer lcsh:Diseases of the genitourinary system. Urology medicine.disease HR hazard ratio PS performance status medicine.anatomical_structure 030220 oncology & carcinogenesis Cohort Original Article Safety medicine.symptom business AE adverse event WBC white blood cell medicine.drug |
Zdroj: | Prostate International Prostate International, Vol 8, Iss 1, Pp 27-33 (2020) |
ISSN: | 2287-8882 |
Popis: | Background: Several studies have reported the efficacy of cabazitaxel in cancer therapy; however, investigations of its safety are few. The aim of this study was to retrospectively analyze the efficacy and safety of cabazitaxel based on treatment outcome data. Methods: A questionnaire form on the use of cabazitaxel was mailed to hospitals associated with the Shinshu University. Responses were received from 11 institutions regarding 55 cases. Results: Patients received a median of 4 courses of cabazitaxel treatment. Decreases in prostrate-specific antigen (PSA) were observed in 61.5% of cases with declines of 30%, 50%, and 90% in 36.5%, 23.0%, and 7.6% of cases, respectively. PSA progression-free survival was 5.0 months, and overall survival after the start of cabazitaxel was 13.0 months. Forty-five patients received postcabazitaxel treatment; 17 showed decreased PSA. Safety assessment indicated that white blood cell and neutrophil counts were significantly higher in the second than in the first course of treatment and Grade 3 to 4 leukopenia and neutropenia significantly decreased. Twenty-four subjects were aged ≥75 years; 79% of them had their doses reduced at the first administration. The mean dose was 20 mg/m2. However, there was no significant difference in the PSA progression-free survival between the ≥75-year-old and |
Databáze: | OpenAIRE |
Externí odkaz: |